Magellan Rx Management, LLC earns URAC Accreditation in Health Utilization Management

EAGAN, Minn. – Feb. 8, 2024 – Prime Therapeutics LLC (Prime) is proud to announce that Magellan Rx Management, LLC (MRx) has earned URAC accreditation for Health Utilization Management (HUM). URAC is the independent leader in promoting health care quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure and risk management. By achieving this status, MRx demonstrates commitment to quality care, enhanced processes, patient safety and improved outcomes.

“It’s gratifying to be endorsed for serving our patients with clinically sound programs that improve the quality and effectiveness of their care while eliminating unnecessary treatment and expense,” said Matthew Mertel, chief operating officer for Prime. “The URAC HUM Accreditation is validation that we’re delivering on our promise to provide the health care experience we want for our loved ones, while ensuring they receive effective and efficient care.”

URAC HUM is an industry standard that indicates MRx performs its utilization management (UM) functions in an effective, transparent and efficient manner. UM is presently seen as a valuable tool to ensure accessibility, quality and timeliness of care. Consequently, URAC keeps pace with the changing health care industry by defining best practices grounded by the real experiences of valued clients and industry experts.

“URAC accreditation shows that MRx adheres to best-in-class industry standards for clinical excellence, collaborative care, patient empowerment, risk management and organizational leadership and accountability. With this distinction, MRx demonstrates excellence in quality health care delivery and their commitment to ensuring patient safety,” said URAC President and CEO Shawn Griffin, M.D.